Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind crossover placebo-controlled study of FT1 in short bowel syndrome
CTR20262563Phase 2Active
- Sponsor
- Chongqing Paijin Biotechnology
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of notoginsenoside Ft1 in short bowel syndrome (SBS), sponsored by Chongqing Paijin Biotechnology. Started Jul 2026; status: active.
02
Drugs
notoginsenoside Ft1
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on CTR20262563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262563.